DiaMedica Therapeutics (NASDAQ:DMAC) Releases Quarterly Earnings Results, Meets Estimates

Posted by Jessica Moore on Nov 12th, 2026

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) issued its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.21), FiscalAI reports.

DiaMedica Therapeutics Trading Down 3.4%

NASDAQ DMAC traded down $0.33 during trading hours on Thursday, hitting $9.33. 187,770 shares of the company’s stock were exchanged, compared to its average volume of 216,847. The stock has a 50-day simple moving average of $8.11 and a 200 day simple moving average of $7.19. DiaMedica Therapeutics has a 1-year low of $5.24 and a 1-year high of $11.00.

Analysts Set New Price Targets

Several research firms have recently commented on DMAC. Wall Street Zen raised DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Thursday, October 15th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $12.00.

Get Our Latest Research Report on DMAC

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.